- level: Info
  location: {}
  message: Importing FHIR PRISM3
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: 'Extracted identifier of type ''Sponsor Protocol Identifier'': ''I8R-JE-IGBJ'''
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: Sponsor org found
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Debug
  location:
    class_name: usdm4_fhir.m11.import_.import_prism3.ImportPRISM3
    method_name: _to_address
  message: 'Address: is valid, {''country'': ''Japan'', ''text'': ''Japan''}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: 'Extracted identifier of type ''Amendment Identifier'': ''I8R-JE-IGBJ(a)'''
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: Co sponsor org not found
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Warning
  location: {}
  message: Unable to extract co-sponsor details from associated parties
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: Local sponsor org not found
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Warning
  location: {}
  message: Unable to extract local sponsor details from associated parties
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: Device manufacturer sponsor org not found
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Warning
  location: {}
  message: Unable to extract device manufacturer details from associated parties
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: 'Scope extracted {''global'': True, ''countries'': [], ''regions'': [],
    ''sites'': [], ''unknown'': []}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: 'Impact extracted {''safety_and_rights'': {''safety'': {''substantial'':
    True, ''reason'': ''Specifically implemented to decrease safety risks.''}, ''rights'':
    {''substantial'': True, ''reason'': ''Specifically implemented to decrease safety
    risks.''}}, ''reliability_and_robustness'': {''reliability'': {''substantial'':
    False, ''reason'': ''''}, ''robustness'': {''substantial'': False, ''reason'':
    ''''}}}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: "Amendment extract {'identifier': 'I8R-JE-IGBJ(a)', 'scope': {'global':\
    \ True, 'countries': [], 'regions': [], 'sites': [], 'unknown': []}, 'enrollment':\
    \ {'value': 0, 'unit': ''}, 'reasons': {'primary': 'Primary: Other', 'secondary':\
    \ 'Secondary: Other'}, 'summary': 'Protocol I8R-JE-IGBJ A Phase 3 Study of Nasal\
    \ Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced\
    \ Hypoglycemia in Japanese Patients with Diabetes Mellitus has been amended. The\
    \ new protocol is indicated by Amendment (a) and will be used to conduct the study\
    \ in place of any preceding version of the protocol. The overall changes and rationale\
    \ for the changes made to this protocol are as follows: \\nAn exclusion criterion\
    \ for patients with retinopathy or maculopathy was added due to the potential\
    \ risk of fundal hemorrhage induced by hypoglycemia. \\nThe GlucaGen reconstitution\
    \ volume was changed from 1.0 mL to 1.1 mL in accordance with instructions in\
    \ the Summary of Product Characteristics (2015). Protocol I8R-JE-IGBJ A Phase\
    \ 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for\
    \ Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes\
    \ Mellitus has been amended. The new protocol is indicated by Amendment (a) and\
    \ will be used to conduct the study in place of any preceding version of the protocol.\
    \ The overall changes and rationale for the changes made to this protocol are\
    \ as follows: \u2022 An exclusion criterion for patients with retinopathy or maculopathy\
    \ was added due to the potential risk of fundal hemorrhage induced by hypoglycemia.\
    \ \u2022 The GlucaGen reconstitution volume was changed from 1.0 mL to 1.1 mL\
    \ in accordance with instructions in the Summary of Product Characteristics (2015).\
    \ Protocol I8R-JE-IGBJ A Phase 3 Study of Nasal Glucagon (LY900018) Compared to\
    \ Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese\
    \ Patients with Diabetes Mellitus has been amended. The new protocol is indicated\
    \ by Amendment (a) and will be used to conduct the study in place of any preceding\
    \ version of the protocol. The overall changes and rationale for the changes made\
    \ to this protocol are as follows: \u2022 An exclusion criterion for patients\
    \ with retinopathy or maculopathy was added due to the potential risk of fundal\
    \ hemorrhage induced by hypoglycemia. \u2022 The GlucaGen reconstitution volume\
    \ was changed from 1.0 mL to 1.1 mL in accordance with instructions in the Summary\
    \ of Product Characteristics (2015).', 'impact': {'safety_and_rights': {'safety':\
    \ {'substantial': True, 'reason': 'Specifically implemented to decrease safety\
    \ risks.'}, 'rights': {'substantial': True, 'reason': 'Specifically implemented\
    \ to decrease safety risks.'}}, 'reliability_and_robustness': {'reliability':\
    \ {'substantial': False, 'reason': ''}, 'robustness': {'substantial': False, 'reason':\
    \ ''}}}, 'changes': [{'description': 'An exclusion criterion for patients with\
    \ retinopathy or maculopathy was added due to the potential risk of fundal hemorrhage\
    \ induced by hypoglycemia.', 'rationale': 'Mitigate risk of fundal hemorrhage\
    \ induced by hypoglycemia.', 'section': 'Section 6'}, {'description': 'The GlucaGen\
    \ reconstitution volume was changed from 1.0 mL to 1.1 mL in accordance with instructions\
    \ in the Summary of Product Characteristics (2015).', 'rationale': 'Ensure alignment\
    \ with Summary of Product Characteristics (2015)', 'section': 'Section 9'}]}"
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Warning
  location: {}
  message: Failed to extract identifier of type 'C218685'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Warning
  location: {}
  message: Failed to extract identifier of type 'C218684'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: 'Extracted identifier of type ''NCT Number'': ''NCT03421379'''
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Debug
  location:
    class_name: usdm4.assembler.identification_assembler.IdentificationAssembler
    method_name: _create_address
  message: 'Creating address, source data: {''country'': ''Japan'', ''text'': ''Japan''}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.identification_assembler.IdentificationAssembler
    method_name: _create_address
  message: Address set to Japan
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Error
  location:
    class_name: usdm4.assembler.identification_assembler.IdentificationAssembler
    method_name: execute
  message: "Failed during creation of identifier {'identifier': 'NCT03421379', 'scope':\
    \ {'standard': 'nct'}}\n\nDetails\n'nct'\n\nTraceback\n  /Users/daveih/Documents/github/usdm4_fhir/.venv/bin/pytest,\
    \ line 8, in <module>\n    sys.exit(console_main())\n  _pytest/config/__init__.py,\
    \ line 206, in console_main\n    code = main()\n  _pytest/config/__init__.py,\
    \ line 178, in main\n    ret: Union[ExitCode, int] = config.hook.pytest_cmdline_main(\n\
    \  pluggy/_hooks.py, line 512, in __call__\n    return self._hookexec(self.name,\
    \ self._hookimpls.copy(), kwargs, firstresult)\n  pluggy/_manager.py, line 120,\
    \ in _hookexec\n    return self._inner_hookexec(hook_name, methods, kwargs, firstresult)\n\
    \  pluggy/_callers.py, line 121, in _multicall\n    res = hook_impl.function(*args)\n\
    \  _pytest/main.py, line 332, in pytest_cmdline_main\n    return wrap_session(config,\
    \ _main)\n  _pytest/main.py, line 285, in wrap_session\n    session.exitstatus\
    \ = doit(config, session) or 0\n  _pytest/main.py, line 339, in _main\n    config.hook.pytest_runtestloop(session=session)\n\
    \  pluggy/_hooks.py, line 512, in __call__\n    return self._hookexec(self.name,\
    \ self._hookimpls.copy(), kwargs, firstresult)\n  pluggy/_manager.py, line 120,\
    \ in _hookexec\n    return self._inner_hookexec(hook_name, methods, kwargs, firstresult)\n\
    \  pluggy/_callers.py, line 121, in _multicall\n    res = hook_impl.function(*args)\n\
    \  _pytest/main.py, line 364, in pytest_runtestloop\n    item.config.hook.pytest_runtest_protocol(item=item,\
    \ nextitem=nextitem)\n  pluggy/_hooks.py, line 512, in __call__\n    return self._hookexec(self.name,\
    \ self._hookimpls.copy(), kwargs, firstresult)\n  pluggy/_manager.py, line 120,\
    \ in _hookexec\n    return self._inner_hookexec(hook_name, methods, kwargs, firstresult)\n\
    \  pluggy/_callers.py, line 121, in _multicall\n    res = hook_impl.function(*args)\n\
    \  _pytest/runner.py, line 116, in pytest_runtest_protocol\n    runtestprotocol(item,\
    \ nextitem=nextitem)\n  _pytest/runner.py, line 135, in runtestprotocol\n    reports.append(call_and_report(item,\
    \ \"call\", log))\n  _pytest/runner.py, line 240, in call_and_report\n    call\
    \ = CallInfo.from_call(\n  _pytest/runner.py, line 341, in from_call\n    result:\
    \ Optional[TResult] = func()\n  _pytest/runner.py, line 241, in <lambda>\n   \
    \ lambda: runtest_hook(item=item, **kwds), when=when, reraise=reraise\n  pluggy/_hooks.py,\
    \ line 512, in __call__\n    return self._hookexec(self.name, self._hookimpls.copy(),\
    \ kwargs, firstresult)\n  pluggy/_manager.py, line 120, in _hookexec\n    return\
    \ self._inner_hookexec(hook_name, methods, kwargs, firstresult)\n  pluggy/_callers.py,\
    \ line 121, in _multicall\n    res = hook_impl.function(*args)\n  _pytest/runner.py,\
    \ line 173, in pytest_runtest_call\n    item.runtest()\n  _pytest/python.py, line\
    \ 1632, in runtest\n    self.ihook.pytest_pyfunc_call(pyfuncitem=self)\n  pluggy/_hooks.py,\
    \ line 512, in __call__\n    return self._hookexec(self.name, self._hookimpls.copy(),\
    \ kwargs, firstresult)\n  pluggy/_manager.py, line 120, in _hookexec\n    return\
    \ self._inner_hookexec(hook_name, methods, kwargs, firstresult)\n  pluggy/_callers.py,\
    \ line 121, in _multicall\n    res = hook_impl.function(*args)\n  anyio/pytest_plugin.py,\
    \ line 160, in pytest_pyfunc_call\n    runner.run_test(pyfuncitem.obj, testargs)\n\
    \  anyio/_backends/_asyncio.py, line 2279, in run_test\n    self.get_loop().run_until_complete(\n\
    \  /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/asyncio/base_events.py,\
    \ line 674, in run_until_complete\n    self.run_forever()\n  /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/asyncio/base_events.py,\
    \ line 641, in run_forever\n    self._run_once()\n  /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/asyncio/base_events.py,\
    \ line 1987, in _run_once\n    handle._run()\n  /Library/Frameworks/Python.framework/Versions/3.12/lib/python3.12/asyncio/events.py,\
    \ line 88, in _run\n    self._context.run(self._callback, *self._args)\n  anyio/_backends/_asyncio.py,\
    \ line 2206, in _run_tests_and_fixtures\n    retval = await coro\n  /Users/daveih/Documents/github/usdm4_fhir/tests/usdm4_fhir/m11/test_m11_integration.py,\
    \ line 175, in test_from_fhir_prism3_igbj\n    await _run_test_from_prism3(\"\
    IGBJ\", SAVE)\n  /Users/daveih/Documents/github/usdm4_fhir/tests/usdm4_fhir/m11/test_m11_integration.py,\
    \ line 92, in _run_test_from_prism3\n    await _run_from_test(name, \"prism3\"\
    , \"import\", save)\n  /Users/daveih/Documents/github/usdm4_fhir/tests/usdm4_fhir/m11/test_m11_integration.py,\
    \ line 98, in _run_from_test\n    wrapper: Wrapper = await instance.from_message(\n\
    \  File \"src/usdm4_fhir/m11/import_/import_prism3.py\", line 48, in from_message\n\
    \    self._assembler.execute(self._source_data)\n  usdm4/assembler/assembler.py,\
    \ line 106, in execute\n    self._identification_assembler.execute(data[\"identification\"\
    ])\n  usdm4/assembler/identification_assembler.py, line 320, in execute\n    self._errors.exception(\n\
    Traceback (most recent call last):\n  usdm4/assembler/identification_assembler.py,\
    \ line 291, in execute\n    copy.deepcopy(self.STANDARD_ORGS[scope[\"standard\"\
    ]])\n                  ~~~~~~~~~~~~~~~~~~^^^^^^^^^^^^^^^^^^^\nKeyError: 'nct'\n"
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.encoder.encoder.Encoder
    method_name: document_status
  message: Document status 'FINAL' decoded as 'C25508', 'Final'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: "Amendment assembler source data {'identifier': 'I8R-JE-IGBJ(a)', 'scope':\
    \ {'global': True, 'countries': [], 'regions': [], 'sites': [], 'unknown': []},\
    \ 'enrollment': {'value': 0, 'unit': ''}, 'reasons': {'primary': 'Primary: Other',\
    \ 'secondary': 'Secondary: Other'}, 'summary': 'Protocol I8R-JE-IGBJ A Phase 3\
    \ Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment\
    \ of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus\
    \ has been amended. The new protocol is indicated by Amendment (a) and will be\
    \ used to conduct the study in place of any preceding version of the protocol.\
    \ The overall changes and rationale for the changes made to this protocol are\
    \ as follows: \\nAn exclusion criterion for patients with retinopathy or maculopathy\
    \ was added due to the potential risk of fundal hemorrhage induced by hypoglycemia.\
    \ \\nThe GlucaGen reconstitution volume was changed from 1.0 mL to 1.1 mL in accordance\
    \ with instructions in the Summary of Product Characteristics (2015). Protocol\
    \ I8R-JE-IGBJ A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular\
    \ Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients\
    \ with Diabetes Mellitus has been amended. The new protocol is indicated by Amendment\
    \ (a) and will be used to conduct the study in place of any preceding version\
    \ of the protocol. The overall changes and rationale for the changes made to this\
    \ protocol are as follows: \u2022 An exclusion criterion for patients with retinopathy\
    \ or maculopathy was added due to the potential risk of fundal hemorrhage induced\
    \ by hypoglycemia. \u2022 The GlucaGen reconstitution volume was changed from\
    \ 1.0 mL to 1.1 mL in accordance with instructions in the Summary of Product Characteristics\
    \ (2015). Protocol I8R-JE-IGBJ A Phase 3 Study of Nasal Glucagon (LY900018) Compared\
    \ to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese\
    \ Patients with Diabetes Mellitus has been amended. The new protocol is indicated\
    \ by Amendment (a) and will be used to conduct the study in place of any preceding\
    \ version of the protocol. The overall changes and rationale for the changes made\
    \ to this protocol are as follows: \u2022 An exclusion criterion for patients\
    \ with retinopathy or maculopathy was added due to the potential risk of fundal\
    \ hemorrhage induced by hypoglycemia. \u2022 The GlucaGen reconstitution volume\
    \ was changed from 1.0 mL to 1.1 mL in accordance with instructions in the Summary\
    \ of Product Characteristics (2015).', 'impact': {'safety_and_rights': {'safety':\
    \ {'substantial': True, 'reason': 'Specifically implemented to decrease safety\
    \ risks.'}, 'rights': {'substantial': True, 'reason': 'Specifically implemented\
    \ to decrease safety risks.'}}, 'reliability_and_robustness': {'reliability':\
    \ {'substantial': False, 'reason': ''}, 'robustness': {'substantial': False, 'reason':\
    \ ''}}}, 'changes': [{'description': 'An exclusion criterion for patients with\
    \ retinopathy or maculopathy was added due to the potential risk of fundal hemorrhage\
    \ induced by hypoglycemia.', 'rationale': 'Mitigate risk of fundal hemorrhage\
    \ induced by hypoglycemia.', 'section': 'Section 6'}, {'description': 'The GlucaGen\
    \ reconstitution volume was changed from 1.0 mL to 1.1 mL in accordance with instructions\
    \ in the Summary of Product Characteristics (2015).', 'rationale': 'Ensure alignment\
    \ with Summary of Product Characteristics (2015)', 'section': 'Section 9'}]}"
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: Amendment reason 'Other' decoded as 'C17649', 'Other'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: Amendment reason 'Other' decoded as 'C17649', 'Other'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.amendments_assembler.AmenementsAssembler
    method_name: _create_scope
  message: Created scope of type Global
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location: {}
  message: 'Scopes created in assembler, geo: [GeographicScope(id=''GeographicScope_2'',
    extensionAttributes=[], type=Code(id=''Code_53'', extensionAttributes=[], code=''C68846'',
    codeSystem=''http://www.cdisc.org'', codeSystemVersion=''2025-09-26'', decode=''Global'',
    instanceType=''Code''), code=None, instanceType=''GeographicScope'')], sites:
    None'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.amendments_assembler.AmenementsAssembler
    method_name: _create_amendment_impact
  message: 'Creating amendment impacts using {''safety_and_rights'': {''safety'':
    {''substantial'': True, ''reason'': ''Specifically implemented to decrease safety
    risks.''}, ''rights'': {''substantial'': True, ''reason'': ''Specifically implemented
    to decrease safety risks.''}}, ''reliability_and_robustness'': {''reliability'':
    {''substantial'': False, ''reason'': ''''}, ''robustness'': {''substantial'':
    False, ''reason'': ''''}}}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.amendments_assembler.AmenementsAssembler
    method_name: _extract_section_numer_and_title
  message: 'Extracted section ref from ''Section 6'' -> {''sectionNumber'': ''6'',
    ''sectionTitle'': '''', ''appliesToId'': ''StudyDefinitionDocument_1'', ''id'':
    ''DocumentContentReference_1'', ''instanceType'': ''DocumentContentReference''}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.amendments_assembler.AmenementsAssembler
    method_name: _extract_section_numer_and_title
  message: 'Extracted section ref from ''Section 9'' -> {''sectionNumber'': ''9'',
    ''sectionTitle'': '''', ''appliesToId'': ''StudyDefinitionDocument_1'', ''id'':
    ''DocumentContentReference_2'', ''instanceType'': ''DocumentContentReference''}'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.encoder.encoder.Encoder
    method_name: phase
  message: Trial phase '3' decoded as 'C15602', 'Phase 3', using M11 decode
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
- level: Info
  location:
    class_name: usdm4.assembler.study_assembler.StudyAssembler
    method_name: _get_study_name_label
  message: Study name set to 'I8RJEIGBJ'
  timestamp: YYYY-MM-DD HH:MM:SS.nnnnnn
  type: ''
